Drugs.com - Clinical Trials

$Linvoseltamab in Combination with Carfilzomib or Bortezomib Shows Promising Initial Results in Earlier Lines of Treatment for Relapsed/Refractory Multiple Myeloma$

Linvoseltamab in Combination with Carfilzomib or Bortez...

May 25, 2025 0

TARRYTOWN, N.Y., May 22, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc...

Apnimed Announces Positive Topline Results in the First Landmark Phase 3 Clinical Trial of AD109, an Investigational Once-Daily Oral Pill for Obstructive Sleep Apnea

Apnimed Announces Positive Topline Results in the First...

May 20, 2025 0

CAMBRIDGE, Mass., May 19, 2025 – Apnimed, Inc., a pharmaceutical company buildin...

Global Phase III Trials Demonstrate That Nerandomilast Slowed Lung Function Decline in IPF and PPF, with Similar Discontinuation Rates to Placebo

Global Phase III Trials Demonstrate That Nerandomilast ...

May 20, 2025 0

Ingelheim, Germany, May 19, 2025 - Boehringer Ingelheim announced today detailed...

IDeate-Esophageal01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Certain Patients with Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma

IDeate-Esophageal01 Phase 3 Trial of Ifinatamab Deruxte...

May 20, 2025 0

Tokyo and Basking Ridge, NJ – May 19, 2025 – The first patient has been dosed in...

Infant with Carbamoyl Phosphate Synthetase 1 (CPS1) Deficiency First to Successfully Receive Personalized Gene Therapy Treatment

Infant with Carbamoyl Phosphate Synthetase 1 (CPS1) Def...

May 20, 2025 0

Thursday, May 15, 2025 -- A research team supported by the National Institutes o...

Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy

Alterity Therapeutics Granted U.S. FDA Fast Track Desig...

May 18, 2025 0

MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 5 May 2025 Alterity Therapeutics ...

BioInvent Receives FDA Fast Track Designation for BI-1808 for the Treatment of Cutaneous T-Cell Lymphoma

BioInvent Receives FDA Fast Track Designation for BI-18...

May 18, 2025 0

Lund, Sweden – April 29, 2025 – BioInvent International AB (“BioInvent”) (Nasdaq...

Sebela Pharmaceuticals Announces Positive Topline Results from Phase 3 TRIUMpH Program of Tegoprazan in GERD

Sebela Pharmaceuticals Announces Positive Topline Resul...

May 18, 2025 0

BRAINTREE, Mass., April 23, 2025 /PRNewswire/ – Braintree Laboratories, a part o...

The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1

The New England Journal of Medicine Publishes Data from...

May 15, 2025 0

OSAKA, Japan and CAMBRIDGE, Massachusetts, May 14, 2025 – Takeda (TSE: 4502/NYSE...

In New SELECT Trial Analysis, Early Reduction in Cardiovascular Events Was Observed with Wegovy®, Before Clinically Meaningful Changes in Body Weight

In New SELECT Trial Analysis, Early Reduction in Cardio...

May 14, 2025 0

PLAINSBORO, N.J., May 13, 2025 /PRNewswire/ -- Today, Novo Nordisk will present ...

Final Data From the Phase 3 MYR301 Study Demonstrated Longer Treatment With Bulevirtide Was Associated With Sustaining Undetectability After Stopping Treatment

Final Data From the Phase 3 MYR301 Study Demonstrated L...

May 14, 2025 0

FOSTER CITY, Calif.--(BUSINESS WIRE) May 7, 2025 -- Gilead Sciences Inc. (Nasdaq...

Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial of Efruxifermin in the New England Journal of Medicine

Akero Therapeutics Announces Publication of Phase 2b SY...

May 12, 2025 0

SOUTH SAN FRANCISCO, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics...

Johnson & Johnson’s TAR-200 Monotherapy Demonstrates Highest Complete Response Rate with Sustained Clinical Benefits in Patients with Certain Types of Bladder Cancer

Johnson & Johnson’s TAR-200 Monotherapy Demonstrates Hi...

May 12, 2025 0

LAS VEGAS, April 26, 2025 – Johnson & Johnson (NYSE: JNJ) today announced new da...

Boehringer’s New Zongertinib Data Demonstrates Durable and Clinically Meaningful Results in Patients with HER2 (ERBB2)-Mutant Advanced NSCLC

Boehringer’s New Zongertinib Data Demonstrates Durable ...

May 12, 2025 0

Ingelheim, Germany / Ridgefield, Conn., U.S., April 28, 2025 - Boehringer Ingelh...

Johnson & Johnson’s TAR-200 Monotherapy Achieves High Disease-Free Survival of More Than 80 Percent in BCG-Unresponsive, High-Risk Papillary NMIBC

Johnson & Johnson’s TAR-200 Monotherapy Achieves High D...

May 12, 2025 0

LAS VEGAS, April 26, 2025 – Johnson & Johnson (NYSE: JNJ) today announced first ...

Pfizer’s Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer

Pfizer’s Sasanlimab Combination Significantly Improves ...

May 12, 2025 0

NEW YORK--(BUSINESS WIRE) April 26, 2025 -- Pfizer Inc. (NYSE: PFE) today announ...

FDA Accepts Filing Application for Oral Semaglutide 25 mg, Which If Approved, Would Be The First Oral GLP-1 Treatment for Obesity

FDA Accepts Filing Application for Oral Semaglutide 25 ...

May 12, 2025 0

PLAINSBORO, N.J., May 2, 2025 /PRNewswire/ -- Today, Novo Nordisk announced that...

ESSENCE Phase 3 Trial of Semaglutide Showed Significant Improvements at 72 Weeks in Adults with MASH, Published in NEJM

ESSENCE Phase 3 Trial of Semaglutide Showed Significant...

May 12, 2025 0

PLAINSBORO, N.J., April 30, 2025 /PRNewswire/ -- Today, The New England Journal ...

AI Screening for Opioid Use Disorder Associated with Fewer Hospital Readmissions

AI Screening for Opioid Use Disorder Associated with Fe...

May 12, 2025 0

April 3, 2025 -- An artificial intelligence (AI)-driven screening tool, develope...

Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease

Biogen’s Investigational Tau-Targeting Therapy BIIB080 ...

May 12, 2025 0

CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) ...

Combination Immunotherapy Shrank a Variety of Metastatic Gastrointestinal Cancers

Combination Immunotherapy Shrank a Variety of Metastati...

May 12, 2025 0

April 1, 2025 -- A new form of tumor infiltrating lymphocyte (TIL) therapy, a fo...

Genentech and Roche Present Novel Therapeutic and Diagnostic Advancements in Alzheimer’s at AD/PD 2025

Genentech and Roche Present Novel Therapeutic and Diagn...

May 12, 2025 0

South San Francisco, CA -- April 3, 2025 -- Genentech, a member of the Roche Gro...

BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program

BeiGene Provides Update on the Ociperlimab (BGB-A1217) ...

May 12, 2025 0

SAN CARLOS, Calif.--(BUSINESS WIRE) April 3, 2025 -- BeiGene, Ltd. (NASDAQ: ONC;...

Rilzabrutinib Granted Orphan Drug Designation in the US for Two Rare Diseases with No Approved Medicines

Rilzabrutinib Granted Orphan Drug Designation in the US...

May 12, 2025 0

Paris, April 3, 2025. The US Food and Drug Administration (FDA) has granted orph...

1
2
3

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.